Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EchiTAb G
- Development stage
- Phase 3
- Lead developer
- MicroPharm
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EchiTAb G is a monospecific, ovine-derived immunoglobulin G (IgG) antivenom developed to treat systemic envenoming caused by the saw-scaled or carpet viper (*Echis ocellatus*), which is responsible for the majority of snakebite-related deaths in Nigeria and the West African savannah. Developed under a collaboration between the Nigerian Federal Ministry of Health and the EchiTAb Study Group, and manufactured by MicroPharm Ltd in Wales, UK, EchiTAb G consists of caprylic acid-purified whole IgG antibodies raised in sheep against *E. ocellatus* venom. It works by neutralizing the lethal, hemorrhagic, and coagulopathic toxins of the venom, thereby restoring blood coagulability in patients suffering from venom-induced consumption coagulopathy. In a Phase II/III clinical trial in Nigeria, EchiTAb G demonstrated a 75.7% rate of permanent restoration of blood coagulability within 6 hours of administration.
- Brand names
- EchiTAb G
- Other names
- EchiTAbGEchiTAb-GEchis ocellatus antivenom (ovine)
02
Targets
EoCTLP (Echis ocellatus venom C-type lectin-like protein)LAAO (L-amino-acid oxidase (Echis ocellatus))EoVMPs (Echis ocellatus venom metalloproteinases)svPLA2 (Echis ocellatus venom phospholipase A2)SVSP (Snake venom serine protease)EoV (Echis ocellatus venom)
Beyond the preview
Go deeper on EchiTAb G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EchiTAb G.